Brief: Equillium Presents Positive Data From Phase 1B Equalise Study
13/11/2023 15:16
Nov 13 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM PRESENTS POSITIVE DATA FROM PHASE 1B EQUALISE
STUDY AT
THE 2023 ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY
Source text for Eikon: ID:nBw6Yf5dGa
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations